Visudyne® in Occult (VIO)
NCT00121407 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 364
Last updated 2005-07-21
Summary
The purpose of this study is to demonstrate that Visudyne therapy in patients who have occult with no classic subfoveal choroidal neovascularization (CNV) lesions will, with an acceptable safety profile, significantly reduce the risk of vision loss compared with placebo (sham treatment).
Conditions
- Macular Degeneration
Interventions
- DRUG
-
Visudyne for injection
Sponsors & Collaborators
-
QLT Inc.
lead INDUSTRY
Principal Investigators
-
Joel Naor, MD · QLT Inc.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-03-31
- Completion
- 2005-08-31
More Related Trials
-
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
NCT00913744 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06628947 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
NCT02599064 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
NCT00056823 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD)
NCT05831007 ·Status: UNKNOWN ·Phase: NA
-
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
NCT00090532 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
NCT03869684 ·Status: TERMINATED ·Phase: PHASE2
-
ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
NCT04744662 ·Status: COMPLETED ·Phase: PHASE1
-
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
NCT05919693 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
NCT04895293 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887 ·Status: RECRUITING ·Phase: PHASE2
-
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
NCT02357342 ·Status: COMPLETED ·Phase: PHASE2
-
Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
NCT00457678 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy
NCT03173638 ·Status: UNKNOWN ·Phase: PHASE2
-
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
NCT04919473 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
NCT02713204 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
NCT00712491 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma
NCT05706896 ·Status: RECRUITING ·Phase: NA
-
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
NCT01027650 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
NCT00658619 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
NCT01601483 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
NCT06852963 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
NCT00211458 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
NCT01301443 ·Status: COMPLETED ·Phase: PHASE1
-
An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa
NCT00661479 ·Status: COMPLETED ·Phase: PHASE1/PHASE2